Mogadon (Nitrazepam)

Nitrazepam, the active ingredient in Mogadon, is a benzodiazepine presented as an oral tablet for systemic use. It is indicated for short‑term treatment of insomnia, for severe anxiety disorders, and as adjunct therapy in certain seizure disorders or pre‑operative sedation.

GNH USA supplies Mogadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before release. The product is distributed through a secure cold‑chain‑free logistics network ensuring tablet integrity during transit.

Nitrazepam, a benzodiazepine that enhances GABA‑mediated inhibition, is employed for several central nervous system conditions. - Insomnia: short‑term improvement of sleep onset and maintenance in adults. - Severe anxiety disorders: reduction of excessive anxiety and tension when other treatments are insufficient. - Seizure disorders: adjunct therapy to control certain types of seizures, such as myoclonic or Lennox‑Gastaut syndrome. - Pre‑operative sedation: short‑acting calming effect to facilitate anesthesia induction.

Nitrazepam may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Drowsiness: persistent daytime sleepiness that may affect alertness. - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain often reported after initiation. - Memory disturbance: difficulty recalling recent information or events.

Serious or Rare Side Effects: - Respiratory depression: marked slowing of breathing, particularly when combined with alcohol or other depressants. - Dependence and withdrawal: potential for physical dependence and withdrawal symptoms after prolonged therapy. - Severe allergic reaction: rash, facial swelling, or anaphylaxis requiring immediate medical care. - Paradoxical agitation: unexpected increase in anxiety, aggression, or restlessness.

When prescribing Nitrazepam, clinicians should consider several safety precautions to minimize risks. - Patient assessment: evaluate history of substance abuse, depression, or respiratory disorders before initiating therapy. - Duration of use: limit treatment to the shortest effective period, typically no longer than 2–4 weeks, to reduce dependence risk. - Concomitant CNS depressants: avoid or closely monitor use with alcohol, opioids, or other sedatives. - Pregnancy and lactation: contraindicated in pregnancy (Category D) and not recommended while breastfeeding. - Elderly patients: start at lower doses and monitor for falls, confusion, or excessive sedation. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nit